What is Dimethyl fumarate?
Category: Prescription Drugs
Most popular types: Tecfidera
Dimethyl fumarate is primarily used for the treatment of relapsing remitting MS. It is an oral medication and is used to help reduce the number of relapses a patient experiences.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 7647 | 948 | |
| Participate in clinical trial | 13 | 13 | |
| Psoriasis | 2 | 4 | |
| Arthritis pain | 1 | 0 | |
| Brain atrophy cerebrum | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 148 | |
| Moderate | 176 | |
| Mild | 385 | |
| None | 251 |
Commonly reported side effects and conditions associated with Dimethyl fumarate
| Side effect | Patients | Percentage |
|---|---|---|
| Flushing | 201 | |
| Facial flushing | 66 | |
| Diarrhea | 59 | |
| Nausea | 55 | |
| Stomach pain | 46 | |
| Itching | 30 |
Why patients stopped taking Dimethyl fumarate
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 178 | |
| Doctor's advice | 116 | |
| Did not seem to work | 86 | |
| Other | 55 | |
| Course of treatment ended | 14 | |
| Personal research | 12 | |
| Expense | 8 | |
| Change in health plan coverage | 7 |
Duration
Stopped taking Dimethyl fumarate
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 66 | |
| 1 - 6 months | 74 | |
| 6 months - 1 year | 57 | |
| 1 - 2 years | 66 | |
| 2 - 5 years | 73 | |
| 5 - 10 years | 5 | |
| 10 years or more | 4 |
What people switch to and from
Patients started taking Dimethyl fumarate after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Glatiramer acetate (Copaxone) | 153 | |
| Interferon beta-1a IM Injection (Avonex) | 72 | |
| Interferon beta-1a SubQ injection (Rebif) | 69 | |
| Natalizumab (Tysabri) | 56 | |
| Interferon beta-1b SubQ Injection (Betaseron) | 33 |
Patients stopped taking Dimethyl fumarate and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Teriflunomide (Aubagio) | 66 | |
| Glatiramer acetate (Copaxone) | 47 | |
| Natalizumab (Tysabri) | 45 | |
| Fingolimod (Gilenya) | 39 | |
| Ocrelizumab (Ocrevus) | 37 |
Last updated: